MA67594B1 - Composition aqueuse - Google Patents

Composition aqueuse

Info

Publication number
MA67594B1
MA67594B1 MA67594A MA67594A MA67594B1 MA 67594 B1 MA67594 B1 MA 67594B1 MA 67594 A MA67594 A MA 67594A MA 67594 A MA67594 A MA 67594A MA 67594 B1 MA67594 B1 MA 67594B1
Authority
MA
Morocco
Prior art keywords
aqueous composition
vessel
ester
acceptable salt
pharmacologically acceptable
Prior art date
Application number
MA67594A
Other languages
English (en)
French (fr)
Other versions
MA67594A1 (fr
Inventor
Rika ORITANI
Chise KITANI
Akinori Nishimoto
Original Assignee
Tsubota Laboratory, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsubota Laboratory, Inc. filed Critical Tsubota Laboratory, Inc.
Publication of MA67594A1 publication Critical patent/MA67594A1/fr
Publication of MA67594B1 publication Critical patent/MA67594B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MA67594A 2022-03-25 2023-03-24 Composition aqueuse MA67594B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022050275 2022-03-25
PCT/JP2023/011739 WO2023182480A1 (ja) 2022-03-25 2023-03-24 水性組成物

Publications (2)

Publication Number Publication Date
MA67594A1 MA67594A1 (fr) 2025-07-31
MA67594B1 true MA67594B1 (fr) 2026-01-30

Family

ID=88101709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA67594A MA67594B1 (fr) 2022-03-25 2023-03-24 Composition aqueuse

Country Status (14)

Country Link
US (1) US20250213510A1 (cg-RX-API-DMAC7.html)
EP (1) EP4483867A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023182480A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240159636A (cg-RX-API-DMAC7.html)
CN (1) CN118973561A (cg-RX-API-DMAC7.html)
AU (1) AU2023240729A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254664A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002831A1 (cg-RX-API-DMAC7.html)
IL (1) IL315871A (cg-RX-API-DMAC7.html)
MA (1) MA67594B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011634A (cg-RX-API-DMAC7.html)
PE (1) PE20250746A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400133A (cg-RX-API-DMAC7.html)
WO (1) WO2023182480A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026130361A1 (zh) * 2024-12-17 2026-06-25 沈阳兴齐眼药股份有限公司 药物组合物、其制备方法及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005330271A (ja) * 2004-04-20 2005-12-02 Taisho Pharmaceut Co Ltd 点眼用液剤
JP2013525451A (ja) * 2010-04-28 2013-06-20 ザ・チャイニーズ・ユニバーシティ・オブ・ホンコン 高眼圧症及び緑内障を予防及び治療する方法及び薬物
JP2016065095A (ja) * 2008-05-30 2016-04-28 参天製薬株式会社 高眼圧症及び緑内障を治療するための方法及び組成物
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
WO2020129965A1 (ja) * 2018-12-18 2020-06-25 参天製薬株式会社 4-フェニル酪酸を含有する老視の治療または予防剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
JP2009078977A (ja) * 2007-09-25 2009-04-16 Japan Health Science Foundation 心筋の小胞体ストレス抑制剤
EP2698155A1 (en) * 2012-08-16 2014-02-19 Lunamed AG Pharmaceutical unit dosage form comprising 4-phenylbutyric acid
CN111024960B (zh) * 2019-12-27 2023-02-17 广州阳普医疗科技股份有限公司 用于高血压血样检测的添加剂、试剂盒和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005330271A (ja) * 2004-04-20 2005-12-02 Taisho Pharmaceut Co Ltd 点眼用液剤
JP2016065095A (ja) * 2008-05-30 2016-04-28 参天製薬株式会社 高眼圧症及び緑内障を治療するための方法及び組成物
JP2013525451A (ja) * 2010-04-28 2013-06-20 ザ・チャイニーズ・ユニバーシティ・オブ・ホンコン 高眼圧症及び緑内障を予防及び治療する方法及び薬物
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
WO2020129965A1 (ja) * 2018-12-18 2020-06-25 参天製薬株式会社 4-フェニル酪酸を含有する老視の治療または予防剤

Also Published As

Publication number Publication date
EP4483867A1 (en) 2025-01-01
WO2023182480A1 (ja) 2023-09-28
US20250213510A1 (en) 2025-07-03
KR20240159636A (ko) 2024-11-05
CN118973561A (zh) 2024-11-15
MX2024011634A (es) 2024-09-30
IL315871A (en) 2024-11-01
CL2024002831A1 (es) 2025-01-24
MA67594A1 (fr) 2025-07-31
EP4483867A4 (en) 2026-06-24
TW202400133A (zh) 2024-01-01
JPWO2023182480A1 (cg-RX-API-DMAC7.html) 2023-09-28
AU2023240729A1 (en) 2024-10-03
CA3254664A1 (en) 2025-07-03
PE20250746A1 (es) 2025-03-13

Similar Documents

Publication Publication Date Title
MA67594A1 (fr) Composition aqueuse
Brill et al. The passage of tissue fluid into the clinically healthy gingival pocket
Winum et al. Therapeutic potential of sulfamides as enzyme inhibitors
FR2424311A1 (fr) Compositions de nettoyage pour des lentilles de contact, a base d'uree ou d'un sel d'acide avec la guanidine, et d'un reducteur
JP2011517318A5 (cg-RX-API-DMAC7.html)
FR2356600A1 (fr) Agent germicide pour systemes aqueux a base de peroxyde d'hydrogene et son utilisation
CA3240524A1 (en) E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
FR2410630A1 (fr) Procede pour preparer des composes de type pyrochlore riches en plomb et riches en bismuth avec un milieu alcalin
Greenbaum et al. The in vitro inactivation and formation of plasma kinins by spleen cathepsins
Fernando et al. Fructose diphosphatase from rabbit muscle: II. Amino acid composition and activation by sulfhydryl reagents
WO2019144692A1 (zh) 一种胰高血糖素保护剂及其应用
CN104059794A (zh) 一种分析仪的清洗液
Werle Discovery of the most important kallikreins and kallikrein inhibitors
ES2121955T3 (es) Composiciones detergentes para lavavajillas.
Caygill et al. Presence of glucosaminidase activity in human synovial fluid and its inhibition by gold compounds
Bahgat et al. Serine protease and phenoloxidase activities in hemocytes of Biomphalaria glabrata snails with varying susceptibility to infection with the parasite Schistosoma mansoni
DK49492A (da) Trifluormethansulfonater og fremgangsmaade til fremstilling deraf
Cox et al. Preliminary studies on cysteine and serine proteinase activities in inflamed human gingiva using different 7-amino-4-trifluoromethyl coumarin substrates and protease inhibitors
GB863739A (en) Diagnostic preparation for the determination of serum alkaline phosphatase
Stauber et al. Fluorescence demonstration of cathepsin B activity in skeletal, cardiac, and vascular smooth muscle.
FR2425474A1 (fr) Procede de production de compositions detergentes
Siems et al. Angiotensin‐converting enzyme and other peptidolytic enzymes in human semen and relations to its spermatologic parameters
FR3131693B1 (fr) Composition pour le traitement de fibres kératineuses, comprenant un silicate soluble dans l'eau et un acide soluble dans l'eau
FR2365340A1 (fr) Composition pharmaceutique contenant des phenylglycines l ou dl (racemiques)
Walker et al. Pepsin 5 in gastric juice: determination and relationship to the alkali-stable peptic activity.